These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29718378)

  • 1. Evaluation of Total and IgA-Specific Antibody Targeting Epstein-Barr Virus Glycoprotein 350 and Nasopharyngeal Carcinoma Risk.
    Coghill AE; Bu W; Hsu WL; Nguyen H; Yu KJ; Chien YC; Chen CJ; Cohen JI; Hildesheim A
    J Infect Dis; 2018 Aug; 218(6):886-891. PubMed ID: 29718378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
    Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
    Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein-Barr virus capsid antigen: A mediation analysis.
    Hsu WL; Chien YC; Huang YT; Yu KJ; Ko JY; Lin CY; Tsou YA; Leu YS; Liao LJ; Chang YL; Su JY; Liu Z; Wang CP; Terng SD; Hua CH; Lee JC; Yang TL; Kate Hsiao CH; Wu MS; Tsai MH; Liu MJ; Lou PJ; Hildesheim A; Chen CJ;
    Cancer Med; 2020 Mar; 9(5):1867-1876. PubMed ID: 31925935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
    Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
    mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus and human papillomavirus serum antibodies define the viral status of nasopharyngeal carcinoma in a low endemic country.
    Simon J; Schroeder L; Ingarfield K; Diehl S; Werner J; Brenner N; Liu Z; Pawlita M; Pring M; Butt J; Ness A; Waterboer T
    Int J Cancer; 2020 Jul; 147(2):461-471. PubMed ID: 32279316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroreactivity against Epstein-Barr virus (EBV) among first-degree relatives of sporadic EBV-associated nasopharyngeal carcinoma in Indonesia.
    Hutajulu SH; Ng N; Jati BR; Fachiroh J; Herdini C; Hariwiyanto B; Haryana SM; Middeldorp JM
    J Med Virol; 2012 May; 84(5):768-76. PubMed ID: 22431025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnostics of nasopharyngeal carcinoma with Epstein-Barr virus (Herpesviridae, Lymphocryptovirus, HHV-4) serological and molecular markers in cases of undetected primary tumor location.].
    Senyuta NB; Smirnova KV; Kondratova VN; Ignatova AV; Mudunov AM; Dushenkina TE; Liechtenstein AV; Gurtsevich VE
    Vopr Virusol; 2019; 64(5):229-237. PubMed ID: 32167688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between environmental factors and serological Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma in South China.
    Zhou T; Yang DW; He YQ; Xue WQ; Liao Y; Zheng MQ; Jia YJ; Yuan LL; Zhang WL; Zeng YX; Jia WH
    Cancer Med; 2019 Aug; 8(10):4852-4866. PubMed ID: 31241250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases.
    Xu J; Ahmad A; Blagdon M; D'Addario M; Jones JF; Dolcetti R; Vaccher E; Prasad U; Menezes J
    Int J Cancer; 1998 Oct; 79(5):481-6. PubMed ID: 9761116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan.
    Coghill AE; Pfeiffer RM; Proietti C; Hsu WL; Chien YC; Lekieffre L; Krause L; Teng A; Pablo J; Yu KJ; Lou PJ; Wang CP; Liu Z; Chen CJ; Middeldorp J; Mulvenna J; Bethony J; Hildesheim A; Doolan DL
    Clin Cancer Res; 2018 Mar; 24(6):1305-1314. PubMed ID: 29301829
    [No Abstract]   [Full Text] [Related]  

  • 11. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
    Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
    Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
    Luo YL; Chen H; Peng SG; Lin JH; Huang PY
    Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
    Zheng XH; Lu LX; Li XZ; Jia WH
    Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus seroreactivity among unaffected individuals within high-risk nasopharyngeal carcinoma families in Taiwan.
    Pickard A; Chen CJ; Diehl SR; Liu MY; Cheng YJ; Hsu WL; Sun B; Hsu MM; Chen IH; Chen JY; Yang CS; Mittl BL; Chou SP; Ruggles DD; Goldstein AM; Hildesheim A
    Int J Cancer; 2004 Aug; 111(1):117-23. PubMed ID: 15185352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis.
    Xia C; Zhu K; Zheng G
    Int J Clin Exp Pathol; 2015; 8(12):16104-10. PubMed ID: 26884888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
    Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
    J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective evaluation of the relevance of Epstein-Barr virus antibodies for early detection of nasopharyngeal carcinoma in Chinese adults.
    Yang L; Kartsonaki C; Simon J; Yao P; Guo Y; Lv J; Walters RG; Chen Y; Fry H; Avery D; Yu C; Jin J; Mentzer AJ; Allen N; Butt J; Hill M; Li L; Millwood IY; Waterboer T; Chen Z
    Int J Epidemiol; 2024 Jun; 53(4):. PubMed ID: 39008896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of EBV antibody-based NPC risk scores in Taiwan NPC multiplex families.
    Hsu WL; Tao J; Fu S; Yu KJ; Simon J; Chen TC; Chen CJ; Goldstein AM; Yu K; Hildesheim A; Waterboer T; Wang CP; Liu Z
    Int J Cancer; 2024 Oct; 155(8):1400-1408. PubMed ID: 38822730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of association between cigarette smoking and Epstein Barr virus reactivation in the nasopharynx in people with elevated EBV IgA antibody titres.
    Chen Y; Xu Y; Zhao W; Xiao X; Zhou X; Lin L; Huang T; Liao J; Li Y; Zeng X; Huang G; Ye W; Zhang Z
    BMC Cancer; 2018 Feb; 18(1):190. PubMed ID: 29444646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated Epstein-Barr virus seroreactivity among unaffected members of families with nasopharyngeal carcinoma.
    Qin HD; Jia WH; Zhang LL; Liu N; Zhou XX; Wang MH; Feng QS; Chen LZ; Zhang Y; Jorgensen TJ; Zeng YX; Shugart YY
    J Med Virol; 2011 Oct; 83(10):1792-8. PubMed ID: 21837797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.